Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07095517 · ClinicalTrials.gov registry record · Phase 1
Pathways, Risk Factors, and mOleculeS to Prevent Early-onset Colorectal Tumors
A Phase 1 study of Colorectal Adenoma and Colorectal Cancer Prevention, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT07095517: Recruiting Phase 1 study of Colorectal Adenoma and Colorectal Cancer Prevention, sponsored by Massachusetts General Hospital.
NCT07095517 is a Phase 1 study of Colorectal Adenoma and Colorectal Cancer Prevention that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 20 participants, below the 1,428-participant average among 8 other Colorectal Adenoma trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07095517, a Phase 1 study of Colorectal Adenoma and Colorectal Cancer Prevention, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study is an open-label Phase 1 Exploratory/Pilot clinical trial to measure the effects of the incretin mimetic, tirzepatide, on tissue, urine, blood, and microbiome biomarkers associated with colorectal cancer risk and to understand the feasibility of this precision prevention trial approach for a future larger study.
Primary Outcome
To determine the effect of tirzepatide intervention on urinary prostaglandin metabolites (PGE-M), an established CRC risk biomarker, in context of changes in body weight.
Conditions Studied
Interventions
- DRUG Tirzepatide
Study Locations (1)
Massachusetts
- Massachusetts General Hospital Cancer Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2026-02-24 |
| Est. Completion | 2028-12-31 |
| Phase | Phase 1 |
What NCT07095517 shows while recruiting
NCT07095517 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 1,428-participant average among 8 other Colorectal Adenoma trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Colorectal Adenoma appearing as the primary indexed condition, and to 1 intervention - of which Tirzepatide is the first listed.
NCT07095517 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT07095517 about?
NCT07095517 is a clinical study titled "Pathways, Risk Factors, and mOleculeS to Prevent Early-onset Colorectal Tumors". This research study is an open-label Phase 1 Exploratory/Pilot clinical trial to measure the effects of the incretin mimetic, tirzepatide, on tissue, urine, blood, and microbiome biomarkers associated with colorectal cancer risk and to understand the feasibility of this precision prevention trial ap...
What is the current status of trial NCT07095517?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2026-02-24. Estimated completion is 2028-12-31.
What conditions does trial NCT07095517 study?
This clinical trial studies the following conditions: Colorectal Adenoma, Colorectal Cancer Prevention.
What interventions are being tested in trial NCT07095517?
The interventions under investigation include: Tirzepatide (DRUG).
Who is sponsoring clinical trial NCT07095517?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07095517 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Adenoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07095517's enrollment target sits among peer trials
20 9th of 8 the lowest of 8 other Colorectal Adenoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Colorectal Adenoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of Gixam's Performance in a FIT Negative Population
RECRUITING · Phase 2
-
PARADIGM - En Bloc Trial With the EndoQuest Endoluminal Surgical (ELS) System
RECRUITING · NA
-
Colonoscopy vs Stool Testing for Older Adults With Colon Polyps
RECRUITING · NA
-
Vaccine Therapy in Treating Patients With Newly Diagnosed Advanced Colon Polyps
ACTIVE NOT RECRUITING · Phase 2
-
Aspirin in Preventing Colorectal Cancer in Patients With Colorectal Adenoma
ACTIVE NOT RECRUITING · Phase 2
-
Linaclotide in Treating Patients With Stages 0-3 Colorectal Cancer
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI